Table 1 Demographics, clinicopathological, and treatment characteristics of patients with or without recurrence
From: Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma
Variables | All patients (N = 141) | Recurrence (N = 97) | No recurrence (N = 44) |
|---|---|---|---|
Age(years) | |||
≤ 74 | 116(82.3%) | 79(81.4%) | 37(84.1%) |
≥ 75 | 25(17.7%) | 18(18.6%) | 7(15.9%) |
Sex (%) | |||
Male | 80(56.7%) | 59(60.8%) | 21(47.7%) |
Female | 61(43.3%) | 38(39.2%) | 23(52.3%) |
BMI (kg/m2) | |||
≤ 18.4 | 10(7.1%) | 6(6.2%) | 4(9.1%) |
≥ 18.5 | 131(92.9%) | 91(93.8%) | 40(90.9%) |
Surgical Procedure | |||
RAMPS | 67(47.5%) | 43(44.3%) | 24(54.5%) |
DP | 74(52.5%) | 54(55.7%) | 20(45.5%) |
Preoperative CA19-9 (U/L) | |||
≤ 37 | 32(22.7%) | 19(19.6%) | 13(29.5%) |
> 37 | 109(77.3%) | 78(80.4%) | 31(70.5%) |
Postoperative CA19-9 (U/L) | |||
≤ 37 | 81(57.4%) | 48(49.5%) | 33(75%) |
> 37 | 60(42.6%) | 49(50.5%) | 11(25%) |
T stage | |||
T1-2 | 93(66.0%) | 63(64.9%) | 30(68.2%) |
T3-4 | 48(34.0%) | 34(35.1%) | 14(31.8%) |
N stage | |||
N0 | 91(64.5%) | 55(56.7%) | 36(81.8%) |
N1-2 | 50(35.5%) | 42(43.3%) | 8(18.2%) |
Tumor differentiation | |||
Well /moderate | 71(51.1%) | 46(47.4%) | 25(59.5%) |
Poor | 68(48.9%) | 51(52.6%) | 17(40.5%) |
R-status | |||
R1 | 6(4.3%) | 4(4.1%) | 2(4.8%) |
R0 | 133(95.7%) | 93(95.9%) | 40(95.2%) |
Perineural invasion | |||
Yes | 110(79.1%) | 76(78.4%) | 34(81.0%) |
No | 29(20.9%) | 21(21.6%) | 8(19.0%) |
Lymphovasular invasion | |||
Yes | 51(36.7%) | 37(38.1%) | 14(33.3%) |
No | 88(63.3%) | 60(61.9%) | 28(66.7%) |
Neoadjuvant chemotherapy | |||
Yes | 14(9.9%) | 12(12.4%) | 2(4.5%) |
No | 127(90.1%) | 85(87.6%) | 42(95.5%) |
Adjuvant chemotherapy | |||
Yes | 82(58.2%) | 51(52.6%) | 31(70.5%) |
No | 59(41.8%) | 46(47.4%) | 13(29.5%) |